Parkwalk are delighted to welcome Oxford Brain Diagnostics to its portfolio following an investment from the University of Oxford Innovation Fund IV.

Oxford Brain Diagnostics’ (OBD) goal is to change the diagnosis and treatment of Alzheimer’s disease by enabling early and accurate detection using our patented Cortical Disarray Measurement technology. OBD provides new technology for pharmaceutical trials to transform the drug discovery process, enabling faster, cheaper and more accurate testing.

OBD has developed a new method that directly measures the cellular health of patients’ brain circuits from standard MRI data.  The result is a unique microanatomical assessment which can predict which people with mild memory complaints will develop dementia within the next few years